Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Addition of CMLVAX100 to conventional treatment in patients with chronic myeloid leukaemia might favour further reduction of residual disease and increase the number of patients reaching a molecular response.
657-662
Bocchia, M.
469a1dc3-f5f8-4aa9-8837-6906eb0a23b3
Gentili, S.
d6ea9f67-f209-4012-abff-dc2677f47d3d
Abruzzese, E.
39821d71-5106-4c09-8d55-b58fe5e6f71a
Fanelli, A.
f9c3599a-e0c3-4eac-9db6-a9e548ded133
Iuliano, F.
b1b52c19-83cd-4b4c-8fde-08dc2ec8e6a8
Tabilio, A.
13fbae62-64dd-4793-b755-022bd408e793
Amabile, M.
9443e54a-e305-455a-bfea-3cab90d6f157
Forconi, F.
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Gozzetti, A.
2dd19886-f8ce-422b-afba-23a8ab0423d5
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Amadori, S.
36da3dc5-7c43-4e5f-bbd5-d6d944c37a92
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
February 2005
Bocchia, M.
469a1dc3-f5f8-4aa9-8837-6906eb0a23b3
Gentili, S.
d6ea9f67-f209-4012-abff-dc2677f47d3d
Abruzzese, E.
39821d71-5106-4c09-8d55-b58fe5e6f71a
Fanelli, A.
f9c3599a-e0c3-4eac-9db6-a9e548ded133
Iuliano, F.
b1b52c19-83cd-4b4c-8fde-08dc2ec8e6a8
Tabilio, A.
13fbae62-64dd-4793-b755-022bd408e793
Amabile, M.
9443e54a-e305-455a-bfea-3cab90d6f157
Forconi, F.
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Gozzetti, A.
2dd19886-f8ce-422b-afba-23a8ab0423d5
Raspadori, D.
bf030b4a-d671-41d0-bd9f-fac632ed88c8
Amadori, S.
36da3dc5-7c43-4e5f-bbd5-d6d944c37a92
Lauria, F.
735fa868-573e-4a9b-b409-a3316d397c4a
Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S. and Lauria, F.
(2005)
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
The Lancet, 365 (9460), .
(doi:10.1016/S0140-6736(05)17945-8).
(PMID:15721470)
Abstract
Addition of CMLVAX100 to conventional treatment in patients with chronic myeloid leukaemia might favour further reduction of residual disease and increase the number of patients reaching a molecular response.
This record has no associated files available for download.
More information
Published date: February 2005
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 358172
URI: http://eprints.soton.ac.uk/id/eprint/358172
ISSN: 0140-6736
PURE UUID: 2b751290-97fd-4d07-a6ff-7ec5fda5721b
Catalogue record
Date deposited: 14 Nov 2013 13:54
Last modified: 16 Aug 2024 01:45
Export record
Altmetrics
Contributors
Author:
M. Bocchia
Author:
S. Gentili
Author:
E. Abruzzese
Author:
A. Fanelli
Author:
F. Iuliano
Author:
A. Tabilio
Author:
M. Amabile
Author:
A. Gozzetti
Author:
D. Raspadori
Author:
S. Amadori
Author:
F. Lauria
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
